Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Communication during immediate danger
A frightened child and family need brief, calm information without delaying life-saving assessment or treatment.
Action: Name the clinical lead, use one-sentence explanations before each action, allocate a team member to the family and use closed-loop language within the team. Tell the child what is happening in concrete terms, avoid false reassurance, confirm allergies and critical history, and state when the next update will come. If consent cannot be obtained in time, explain that immediately necessary best-interests treatment is proceeding and document the circumstances. Arrange a professional interpreter as soon as practicable without delaying stabilisation.
Synopsis
Communicate directly, honestly and developmentally with children and young people while supporting families, meeting language and accessibility needs, preserving confidentiality and turning difficult conversations into a clear shared plan.
Address the child first by name, explain your role and ask how they prefer to communicate; parents add essential knowledge but do not replace the child's voice.
Observe before touching: play, gaze, gesture, posture, interaction and response to the caregiver reveal both developmental level and distress.
Use short concrete sentences, one idea at a time, and check meaning; vocabulary must match developmental understanding rather than chronological age alone.
Key red flags
A child who becomes silent, unusually compliant, fearful of an accompanying adult or unable to speak privately may be signalling coercion, abuse or exploitation.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.